Net profit of Glaxosmithkline Pharmaceuticals rose 34.73% to Rs 260.14 crore in the quarter ended March 2025 as against Rs 193.08 crore during the previous quarter ended March 2024. Sales rose 6.06% to Rs 966.08 crore in the quarter ended March 2025 as against Rs 910.87 crore during the previous quarter ended March 2024.
For the full year,net profit rose 57.19% to Rs 919.06 crore in the year ended March 2025 as against Rs 584.69 crore during the previous year ended March 2024. Sales rose 9.28% to Rs 3723.49 crore in the year ended March 2025 as against Rs 3407.25 crore during the previous year ended March 2024.
| Particulars | Quarter Ended | Year Ended |
| Mar. 2025 | Mar. 2024 | % Var. | Mar. 2025 | Mar. 2024 | % Var. |
| Sales | 966.08 | 910.87 | 6 | 3723.49 | 3407.25 | 9 |
| OPM % | 34.24 | 28.03 | - | 31.40 | 26.43 | - |
| PBDT | 369.62 | 284.41 | 30 | 1310.54 | 1022.33 | 28 |
| PBT | 354.90 | 266.31 | 33 | 1243.75 | 952.65 | 31 |
| NP | 260.14 | 193.08 | 35 | 919.06 | 584.69 | 57 |